🔥 biotech 핫 테마 분석

[LLY] Lilly Foundayo is predicted to cut diabetes risk by 57% in late-stage study

S-Class [UTHR] United Therapeutics jumps 13% on court ruling

[NUVB] Nuvation, Jazz gain new Buys at Citi on oncology prospects

[LLY] Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.

The company is working on an experimental amylin drug to see if it can help people lose weight and manage their diabetes — much like a GLP-1.

[LLY] Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial

Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year.

[ABBV] AbbVie's ABBV-295 delivers up to 9.8% weight loss in Phase 1

[NVO] People switching to Novo's Wegovy pill from obesity injections kept losing weight in real-world study

The data on Novo's Wegovy pill suggests that patients may not need to take weekly injections forever, but can instead opt for more convenient treatments.